UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Prof Jeremy Chataway
Department of Neuroinflammation
London
Appointment
  • Professor of Neurology
  • UCL Queen Square Institute of Neurology
  • Faculty of Brain Sciences
Biography

Ten Most Significant Publications

    1. Chataway, J., Martin, K., Barrell, K., Sharrack, B., Stolt, P., Wraith, D., & for the ATX-MS 1467 Study Group. (2018). Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosisNeurology. doi:10.1212/WNL.0000000000005118
    2. Connick, P., De Angelis, F., Parker, R. A., Plantone, D., Doshi, A., John, N.,Chataway J. UK Multiple Sclerosis Society Clinical Trials Network. (2018). Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 8 (8), e021944
    3. Lynch, D. S., Wade, C., Paiva, A. R. B. D., John, N., Kinsella, J. A., Merwick, Á., . . . Chataway, J. (2018). Practical approach to the diagnosis of adult-onset leukodystrophies: An updated guide in the genomic era. Journal of Neurology, Neurosurgery and Psychiatry. doi:10.1136/jnnp-2018-319481
    4. Chan D, Binks S, Nicholas J, Frost C, Cardoso MJ, Ourselin S, Wilkie D, Nicholas R, Chataway J. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality of life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomized, placebo-controlled trial. Lancet Neurology2017 16:591-600.
    5. Fox, R. J., & Chataway, J. (2017). Advancing trial design in progressive multiple sclerosis. MULTIPLE SCLEROSIS JOURNAL, 23 (12), 1573-1578. doi:10.1177/1352458517729768
    6. Ontaneda D, Fox R, Chataway J.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Lancet Neurology 2015 14: 208-23.
    7. Chataway, J.,Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C.R., Clegg, S., Nielsen, C., Fox, N.C., Wilkie, D., Nicholas, J.M., Calder, V.L., Greenwood, J., Frost, C. and Nicholas, R. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 2014 383:2213-2221.
    8. BanerjeeS, Bentley P , Hamady M, Marley S, Marley, Shlebak A, Nicholls J, Williamson D, Jensen S, Gordon M, Habib N, Chataway J. Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke. Stem Cells Translational Medicine. 2014
    9. Chataway, J., Porter, B., Riazi, A., Heaney, D., Watt, H., Hobart, J., & Thompson, A. (2006). Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. The Lancet Neurology, 5 (7), 565-571. doi:10.1016/S1474-4422(06)70450-1
    10. Sawcer, S., Jones, H. B., Feakes, R., Gray, J., Smalldon, N., Chataway, J., . . . Compston, D. A. S. (1996). A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nature Genetics, 13, 464-468.
Research Summary

My research career is centred around clinical trials in neurology. The disease area is dominantly (though not exclusively) multiple sclerosis (MS), and within that, the less tractable secondary progressive stage, SPMS, which accounts for £4bn/year of health care expenditure. The work carried out has received international acclaim, as well as widespread media coverage.

I was Chief Investigator of the MS-STAT1 trial in SPMS  (Lancet 2014) which demonstrated a reduction in brain atrophy (shrinkage) by 43%. It won the UK MS society 2014 research award category.

I lead the MS-SMART trial (£2.8M). It is a flagship study for the entire MS community, testing re-purposed compounds, in a multi-arm fashion.

I have achieved with co-funding from NIHR HTA Board, UK and US MS societies the development of the UK wide MS-STAT2 trial (n=1180). We have started and currently randomised over 250 patients, with 28 sites around the UK.

I co-led the recent 2017 ECTRIMS workshop in association with the International Progressive MS Alliance. The work from this has just been published with a series of 9 papers, of which I am the co-editor (MSJ Special Edition October 2017).

I interact regularly with industry. I was the Chief Investigator of the Apitope/ATX vaccination trial (Neurology 2018)

The Adult Leukodystrophy Group, which I co-funded, goes from strength to strength, and we are currently working with NHS England to commission a National Centre at NHNN/UCLH. Our recent review is: Practical approach to the diagnosis of adult-onset leukodystrophies: An updated guide in the genomic eraJournal of Neurology, Neurosurgery and Psychiatry. doi:10.1136/jnnp-2018-319481

Teaching Summary

  • My core activity is teaching UCL undergraduate medical students in formal lectures and at the bedside (weekly) in neurology.
  • I was involved in setting up regular bedside teaching programme on the neurological wards to improve history taking/examination/analysis. It has been successful and well attended. To supplement this, I have produced a laminated card to aid neurological history and examination.
  • I teach regularly on the UCL/UCLH MRes Translational Neurology and Clinical Neuroscience/Neurology courses. I am fully engaged, setting and marking questions to evaluate participant understanding.Feedback from these is in the very good to excellent range.
  • I was involved in setting the criteria for, and appointing  a statistician to teach and help MSc/PhD students. I am a member of the Library Committee with strong student educational mandate.
  • I set up a NeuroTrials course and teach three times/year on the International Data Monitoring Course hosted by MRC Trials Unit.
  • I organise and participate in the annual UCLPartners patient attended day with audiences of 400; and other patient attended meetings, for example, recently at Guildford and Belfast , with audiences in excess of 200.
  • I review regularly for high impact journals: New England Journal of Medicine (NEJM), Lancet, Lancet Neurology.
  • I am a regular PhD examiner.

Appointments
01-OCT-2018 Professor of Neurology Neuroinflammation UCL, United Kingdom
Please report any queries concerning the data shown on this page to https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by